Back to search results

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Israel
RecruitingPHASE3

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Conditions

Secondary Progressive Multiple Sclerosis (SPMS)

Locations
  • Alabama Neurology Associates PC, Birmingham, Alabama, United States
  • AZ Integrated Neuro and Spine, Phoenix, Arizona, United States
  • Center for Neurosciences, Tucson, Arizona, United States
  • Fullerton Neuro and Headache Ctr, Fullerton, California, United States
  • Regina Berkovich MD PhD Inc, West Hollywood, California, United States
  • Georgetown University Hospital, Washington D.C., District of Columbia, United States
  • Neurology of Central FL Res Ctr, Altamonte Springs, Florida, United States
  • UF Health Cancer Center, Gainesville, Florida, United States
  • Aqualane Clinical Research, Naples, Florida, United States
  • Orlando Health Clinical Trials, Orlando, Florida, United States
  • Comprehensive Neurology Clinic, Orlando, Florida, United States
  • Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States
  • Axiom Brain Health, Tampa, Florida, United States
  • Hawaii Pacific Neuroscience LLC, Honolulu, Hawaii, United States
  • University of Kansas Hospital, Kansas City, Kansas, United States
  • Mid Atlantic Epilepsy and Sleep Ctr, Bethesda, Maryland, United States
  • Michigan Institute of Neurological, Farmington Hills, Michigan, United States
  • Neurology Clinic PC, Cordova, Tennessee, United States
  • Saturn Research Solution, Plano, Texas, United States
  • Novartis Investigative Site, Buenos Aires, Argentina
  • Novartis Investigative Site, Caba, Argentina
  • Novartis Investigative Site, Santiago del Estero, Argentina
  • Novartis Investigative Site, Kogarah, New South Wales, Australia
  • Novartis Investigative Site, New Lambton Heights, New South Wales, Australia
  • Novartis Investigative Site, Westmead, New South Wales, Australia
  • Novartis Investigative Site, Clayton, Victoria, Australia
  • Novartis Investigative Site, Heidelberg, Victoria, Australia
  • Novartis Investigative Site, Pleven, Bulgaria
  • Novartis Investigative Site, Sofia, Bulgaria
  • Novartis Investigative Site, Sofia, Bulgaria
  • Novartis Investigative Site, Sofia, Bulgaria
  • Novartis Investigative Site, Vancouver, British Columbia, Canada
  • Novartis Investigative Site, Lévis, Quebec, Canada
  • Novartis Investigative Site, Montreal, Quebec, Canada
  • Novartis Investigative Site, Montreal, Quebec, Canada
  • Novartis Investigative Site, Montreal, Quebec, Canada
  • Novartis Investigative Site, Sherbrooke, Quebec, Canada
  • Novartis Investigative Site, Wuhan, Hubei, China
  • Novartis Investigative Site, Hohhot, Inner Mongolia, China
  • Novartis Investigative Site, Suzhou, Jiangsu, China
  • Novartis Investigative Site, Hangzhou, Zhejiang, China
  • Novartis Investigative Site, Wenzhou, Zhejiang, China
  • Novartis Investigative Site, Chongqing, China
  • Novartis Investigative Site, Shanghai, China
  • Novartis Investigative Site, Tianjin, China
  • Novartis Investigative Site, Medellín, Colombia
  • Novartis Investigative Site, Medellín, Colombia
  • Novartis Investigative Site, Jihlava, Czechia
  • Novartis Investigative Site, Ajaccio, France
  • Novartis Investigative Site, Amiens, France
  • Novartis Investigative Site, Clermont-Ferrand, France
  • Novartis Investigative Site, Gonesse, France
  • Novartis Investigative Site, Grenoble, France
  • Novartis Investigative Site, Lille, France
  • Novartis Investigative Site, Lille, France
  • Novartis Investigative Site, Montpellier, France
  • Novartis Investigative Site, Nice, France
  • Novartis Investigative Site, Nîmes, France
  • Novartis Investigative Site, Paris, France
  • Novartis Investigative Site, Poitiers, France
  • Novartis Investigative Site, Tours, France
  • Novartis Investigative Site, Freiburg im Breisgau, Baden-Wurttemberg, Germany
  • Novartis Investigative Site, Halle, Saxony-Anhalt, Germany
  • Novartis Investigative Site, Budapest, Hungary
  • Novartis Investigative Site, Kistarcsa, Hungary
  • Novartis Investigative Site, Gurugram, Haryana, India
  • Novartis Investigative Site, Mangalore, Karnataka, India
  • Novartis Investigative Site, Kochi, Kerala, India
  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India
  • Novartis Investigative Site, Vellore, Tamil Nadu, India
  • Novartis Investigative Site, Hyderabad, Telangana, India
  • Novartis Investigative Site, Jerusalem, Israel
  • Novartis Investigative Site, Ramat Gan, Israel
  • Novartis Investigative Site, Rehovot, Israel
  • Novartis Investigative Site, Tel Aviv, Israel
  • Novartis Investigative Site, Ẕerifin, Israel
  • Novartis Investigative Site, Foggia, FG, Italy
  • Novartis Investigative Site, Braga, Portugal
  • Novartis Investigative Site, Lisbon, Portugal
  • Novartis Investigative Site, Bucharest, Romania
  • Novartis Investigative Site, Campulung Muscel, Romania
  • Novartis Investigative Site, Cape Town, Western Cape, South Africa
  • Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain
  • Novartis Investigative Site, Valencia, Valencia, Spain
  • Novartis Investigative Site, Barcelona, Spain
  • Novartis Investigative Site, Málaga, Spain
  • Novartis Investigative Site, Salamanca, Spain
  • Novartis Investigative Site, Bern, Switzerland
  • Novartis Investigative Site, Lausanne, Switzerland
  • Novartis Investigative Site, Glasgow, United Kingdom
View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)